CDKN2B-AS1 and ovarian cancer: Therefore, through in vivo and in vitro experiments, we aimed to investigate whether ANRIL could affect the cisplatin-sensitivity of ovarian cancer by regulating let-7a/HMGA2 axis, so as to look for a novel strategy to alleviate the cisplatin resistance in ovarian cancer.